Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Aripiprazole as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder.
This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Local Institution
Garden Grove, California, United States
Local Institution
Northridge, California, United States
Local Institution
Washington D.C., District of Columbia, United States
Local Institution
Jacksonville, Florida, United States
Local Institution
Chicago, Illinois, United States
Local Institution
Edwardsville, Illinois, United States
Local Institution
Rockville, Maryland, United States
Local Institution
Springfield, Massachusetts, United States
Local Institution
Farmington Hills, Michigan, United States
Local Institution
Okemos, Michigan, United States
Start Date
June 1, 2004
Primary Completion Date
August 1, 2006
Completion Date
August 1, 2006
Last Updated
November 25, 2013
1,200
Estimated participants
Antidepressant + Placebo
DRUG
Antidepressant + Aripiprazole
DRUG
Lead Sponsor
Bristol-Myers Squibb
Collaborators
NCT07115329
NCT06793397
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07025720